Biliary Tract Cancer: T-DXd and Rilvegostomig Study

We are studying a new treatment combination for patients with advanced HER2-expressing biliary tract cancer. The goal is to see if it helps improve survival compared to standard care options.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Imfinzi
Imfinzi is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cisplatin
Cisplatin is a substance used in chemotherapy to kill or stop the growth of cancer cells.
Durvalumab
Durvalumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein tumors use to hide.
Gemcitabine
Gemcitabine is a substance that slows or stops cancer cell growth and is used to treat several cancers, including pancreatic and lung.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Rilvegostomig
Ds-8201a

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Graz
Clinical Division for Oncology
Graz, Austria
Ordensklinikum Linz GmbH
Internal I: Medical Oncology and Hematology
Linz, Austria
SCRI CCCIT Ges.m.b.H.
University Clinic for Internal Medicine III
Salzburg, Austria

Sponsor: AstraZeneca AB
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.